<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04369183</url>
  </required_header>
  <id_info>
    <org_study_id>2019/977</org_study_id>
    <nct_id>NCT04369183</nct_id>
  </id_info>
  <brief_title>Rituximab for Refractory or Relapsed Focal Segmental Glomerulosclerosis or Minimal Change Disease</brief_title>
  <official_title>Efficacy and Safety of Rituximab in Adult Patients With Refractory or Relapsed Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istanbul University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istanbul University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Various studies have been conducted to identify effective treatment strategies for primary
      focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) so far. In the
      light of these studies, corticosteroids and calcineurin inhibitors have been the treatment of
      choice and mycophenolic acid derivatives have been seen as a second line agent. However,
      treatment options in refractory or relapsed cases are still under debate. Recently, rituximab
      has become an alternative in those patients. Therefore, a study based on registry data was
      conducted to evaluate the efficacy and safety of rituximab in adult patients suffering from a
      relapsed or refractory primary FSGS or MCD.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">August 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Remission</measure>
    <time_frame>12 months</time_frame>
    <description>Proteinuria &lt;0.5 g/day, confirmed by two values at least 1 week apart, accompanied by a normal serum albumin concentration, and a normal serum creatinine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Partial Remission</measure>
    <time_frame>12 months</time_frame>
    <description>Proteinuria &lt;3.5 g/day and a 50% or greater reduction from peak values, confirmed by two values at least 1 week apart, accompanied by an improvement or normalization of the serum albumin concentration and stable serum creatinine.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Focal Segmental Glomerulosclerosis</condition>
  <condition>Minimal Change Disease</condition>
  <arm_group>
    <arm_group_label>Study Group</arm_group_label>
    <description>Patients with primary focal segmental glomerulosclerosis or minimal change disease who were treated using rituximab (375 mg/m2/wk for 1-4 weeks) following resistance to or relapse after at least one set of prior therapies including corticosteroids, calcineurin inhibitors or mycophenolic acid derivatives.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with primary focal segmental glomerulosclerosis or minimal change disease who were
        treated using rituximab following resistance to or relapse after at least one set of prior
        therapies including corticosteroids, calcineurin inhibitors or mycophenolic acid
        derivatives.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Having biopsy-proven focal segmental glomerulosclerosis or minimal change disease.

          -  Showing resistance to or relapsing after at least one set of prior therapies including
             corticosteroids, calcineurin inhibitors or mycophenolic acid derivatives.

          -  Having a history of rituximab use (375 mg/m2/wk for 1-4 weeks) following resistance to
             or relapse after aforementioned agents.

        Exclusion Criteria:

          -  Not providing or withdrawing consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Halil Yazici, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Internal Medicine, Istanbul Faculty of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Safak Mirioglu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Internal Medicine, Istanbul Faculty of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Safak Mirioglu, MD</last_name>
    <phone>+902124142000</phone>
    <phone_ext>32149</phone_ext>
    <email>smirioglu@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Halil Yazici, MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Istanbul University</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Safak Mirioglu, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Halil Yazici, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Erdem Gurel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Ruggenenti P, Ruggiero B, Cravedi P, Vivarelli M, Massella L, Maras√† M, Chianca A, Rubis N, Ene-Iordache B, Rudnicki M, Pollastro RM, Capasso G, Pisani A, Pennesi M, Emma F, Remuzzi G; Rituximab in Nephrotic Syndrome of Steroid-Dependent or Frequently Relapsing Minimal Change Disease Or Focal Segmental Glomerulosclerosis (NEMO) Study Group. Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. J Am Soc Nephrol. 2014 Apr;25(4):850-63. doi: 10.1681/ASN.2013030251. Epub 2014 Jan 30.</citation>
    <PMID>24480824</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 25, 2020</study_first_submitted>
  <study_first_submitted_qc>April 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2020</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istanbul University</investigator_affiliation>
    <investigator_full_name>Safak Mirioglu</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>focal segmental glomerulosclerosis</keyword>
  <keyword>minimal change disease</keyword>
  <keyword>rituximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glomerulosclerosis, Focal Segmental</mesh_term>
    <mesh_term>Nephrosis, Lipoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

